{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T20:07:55Z","timestamp":1772136475382,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-95096-6","type":"journal-article","created":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T13:02:16Z","timestamp":1759237336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Risk of tuberculosis and hepatitis B reactivation during adalimumab use in the treatment of hidradenitis suppurativa"],"prefix":"10.1038","volume":"15","author":[{"given":"\u00d6mer","family":"Karakoyun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erhan","family":"Ayhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,30]]},"reference":[{"key":"95096_CR1","doi-asserted-by":"publisher","unstructured":"Cotton, C. H., Chen, S. X., Hussain, S. H., Lara-Corrales, I. & Zaenglein, A. L. Hidradenitis Suppurativa in Pediatric Patients. Pediatrics. ;151(5):e2022061049. (2023). https:\/\/doi.org\/10.1542\/peds.2022-061049. PMID: 37102307.","DOI":"10.1542\/peds.2022-061049"},{"issue":"5","key":"95096_CR2","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","volume":"82","author":"SR Goldburg","year":"2020","unstructured":"Goldburg, S. R., Strober, B. E. & Payette, M. J. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J. Am. Acad. Dermatol. 82 (5), 1045\u20131058. https:\/\/doi.org\/10.1016\/j.jaad.2019.08.090 (2020). Epub 2019 Oct 9. PMID: 31604104.","journal-title":"J. Am. Acad. Dermatol."},{"issue":"5","key":"95096_CR3","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1080\/1744666X.2023.2298356","volume":"20","author":"CA Maronese","year":"2024","unstructured":"Maronese, C. A., Moltrasio, C., Genovese, G. & Marzano, A. V. Biologics for hidradenitis suppurativa: evolution of the treatment paradigm. Expert Rev. Clin. Immunol. 20 (5), 525\u2013545 (2024). Epub 2024 Jan 2. PMID: 38130204.","journal-title":"Expert Rev. Clin. Immunol."},{"issue":"36","key":"95096_CR4","doi-asserted-by":"publisher","first-page":"10274","DOI":"10.3748\/wjg.v21.i36.10274","volume":"21","author":"S Mori","year":"2015","unstructured":"Mori, S. & Fujiyama, S. Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations. World J. Gastroenterol. 21 (36), 10274\u201310289. https:\/\/doi.org\/10.3748\/wjg.v21.i36.10274 (2015). PMID: 26420955; PMCID: PMC4579875.","journal-title":"World J. Gastroenterol."},{"issue":"7","key":"95096_CR5","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1038\/s41423-021-00694-9","volume":"18","author":"M Robert","year":"2021","unstructured":"Robert, M. & Miossec, P. Reactivation of latent tuberculosis with TNF inhibitors: critical role of the beta 2 chain of the IL-12 receptor. Cell. Mol. Immunol. 18 (7), 1644\u20131651. https:\/\/doi.org\/10.1038\/s41423-021-00694-9 (2021). Epub 2021 May 21. PMID: 34021269; PMCID: PMC8245521.","journal-title":"Cell. Mol. Immunol."},{"key":"95096_CR6","doi-asserted-by":"publisher","unstructured":"Kimball, A. B. et al. Adalimumab for the treatment of moderate to severe Hidradenitis suppurativa: a parallel randomized trial. Ann Intern Med. ;157(12):846\u2009\u2013\u200955. (2012). https:\/\/doi.org\/10.7326\/0003-4819-157-12-201212180-00004. PMID: 23247938.","DOI":"10.7326\/0003-4819-157-12-201212180-00004"},{"issue":"4","key":"95096_CR7","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1111\/1756-185X.13401","volume":"22","author":"T Watanabe","year":"2019","unstructured":"Watanabe, T. et al. Incidence and risk factors for reactivation from resolved hepatitis B virus in rheumatoid arthritis patients treated with biological disease-modifying antirheumatic drugs. Int. J. Rheum. Dis. 22 (4), 574\u2013582 (2019). Epub 2018 Oct 18. PMID: 30338649.","journal-title":"Int. J. Rheum. Dis."},{"issue":"11","key":"95096_CR8","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1111\/jdv.14146","volume":"31","author":"S Piaserico","year":"2017","unstructured":"Piaserico, S., Dapavo, P., Conti, A., Gisondi, P. & Russo, F. P. Adalimumab is a safe option for psoriasis patients with concomitant hepatitis B or C infection: a multicenter cohort study of 37 patients and review of the literature. J. Eur. Acad. Dermatol. Venereol. 31 (11), 1853\u20131859. https:\/\/doi.org\/10.1111\/jdv.14146 (2017). Epub 2017 Feb 21. PMID: 28146345.","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"issue":"12","key":"95096_CR9","doi-asserted-by":"publisher","first-page":"e548","DOI":"10.1111\/jdv.14416","volume":"31","author":"DJ No","year":"2017","unstructured":"No, D. J., Amin, M. & Wu, J. J. Adalimumab use in patients with psoriasis and hepatitis B: a case series. J. Eur. Acad. Dermatol. Venereol. 31 (12), e548\u2013e550. https:\/\/doi.org\/10.1111\/jdv.14416 (2017). Epub 2017 Jul 12. PMID: 28622425.","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"95096_CR10","unstructured":"Lee, Y. H., Bae, S. C. & Song, G. G. Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumor necrosis factor therapy. Clin. Exp. Rheumatol. 2013 Jan-Feb ;31(1):118\u2013121. Epub 2012 Oct 30. PMID: 23111095."},{"key":"95096_CR11","unstructured":"Br, J. & Dermatol, V. 180, Issue: 5, Pages: 1009\u20131017, First published: 15 December 2018, DOI: (10.1111\/bjd.17537)."},{"issue":"36","key":"95096_CR12","doi-asserted-by":"publisher","first-page":"10274","DOI":"10.3748\/wjg.v21.i36.10274","volume":"21","author":"S Mori","year":"2015","unstructured":"Mori, S. & Fujiyama, S. Hepatitis B virus reactivation associated with antirheumatic therapy: risk and prophylaxis recommendations. World J. Gastroenterol. 21 (36), 10274\u201310289. https:\/\/doi.org\/10.3748\/wjg.v21.i36.10274 (2015).","journal-title":"World J. Gastroenterol."},{"issue":"6","key":"95096_CR13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","volume":"90","author":"R P\u00e9rez-Alvarez","year":"2011","unstructured":"P\u00e9rez-Alvarez, R. et al. Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. Med. (Baltim). 90 (6), 359\u2013371. https:\/\/doi.org\/10.1097\/MD.0b013e3182380a76 (2011).","journal-title":"Med. (Baltim)."},{"issue":"5","key":"95096_CR14","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/1756-185X.12154","volume":"16","author":"YH Lee","year":"2013","unstructured":"Lee, Y. H., Bae, S. C. & Song, G. G. Hepatitis B virus reactivation in HBsAg-positive patients with rheumatic diseases undergoing anti-tumor necrosis factor therapy or DMARDs. Int. J. Rheum. Dis. 16 (5), 527\u2013531. https:\/\/doi.org\/10.1111\/1756-185X.12154 (2013).","journal-title":"Int. J. Rheum. Dis."},{"issue":"1","key":"95096_CR15","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/j.gastro.2014.10.039","volume":"148","author":"Reddy","year":"2015","unstructured":"ReddyKR et al. American gastroenterological association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy [published correction appears in gastroenterology. 2015;148(2):455. Multiple investigator names added]. Gastroenterology 148 (1), 215\u2013e17. https:\/\/doi.org\/10.1053\/j.gastro.2014.10.039 (2015).","journal-title":"Gastroenterology"},{"key":"95096_CR16","doi-asserted-by":"publisher","unstructured":"Al-Sohaim, A. et al. The risk of tuberculosis infection in 410 Saudipatients receiving adalimumab therapy. Ann. Saudi Med. 41 (5), 285\u2013292. https:\/\/doi.org\/10.5144\/0256-4947.2021.285 (2021 Sep-Oct). Epub 2021 Oct 7. PMID: 34618606; PMCID: PMC8497010.","DOI":"10.5144\/0256-4947.2021.285"},{"key":"95096_CR17","doi-asserted-by":"publisher","unstructured":"Caldera, F., Grimes, I. & Soni, A. Reactivation of latent tuberculosis in a Crohn\u2019s patient after TB prophylaxis treated with adalimumab. Am J Gastroenterol. ;108(7):1181-2. (2013). https:\/\/doi.org\/10.1038\/ajg.2013.144. PMID: 23821003.","DOI":"10.1038\/ajg.2013.144"},{"issue":"1","key":"95096_CR18","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.jaad.2020.01.012","volume":"83","author":"A Ellis","year":"2020","unstructured":"Ellis, A., Khanna, U., Galadari, A. & Fernandez, A. P. Conversion to positive latent tuberculosis infection status is low in patients with hidradenitis suppurativa taking biologic medications. J. Am. Acad. Dermatol. 83 (1), 246\u2013248 (2020). Epub 2020 Jan 12. PMID: 31940465.","journal-title":"J. Am. Acad. Dermatol."},{"issue":"10","key":"95096_CR19","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1093\/rheumatology\/keq183","volume":"49","author":"JF Rahier","year":"2010","unstructured":"Rahier, J. F. et al. Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatol. (Oxford). 49 (10), 1815\u20131827. https:\/\/doi.org\/10.1093\/rheumatology\/keq183 (2010).","journal-title":"Rheumatol. (Oxford)"},{"issue":"4","key":"95096_CR20","doi-asserted-by":"publisher","first-page":"375","DOI":"10.23736\/S2784-8671.24.07895-2","volume":"159","author":"G Ciccarese","year":"2024","unstructured":"Ciccarese, G. et al. Anti-Herpes Zoster vaccination in patients with dermatologic diseases: a position statement from the Italian sidemast group of sexually transmitted, infectious and tropical diseases. Ital. J. Dermatol. Venerol. 159 (4), 375\u2013379. https:\/\/doi.org\/10.23736\/S2784-8671.24.07895-2 (2024).","journal-title":"Ital. J. Dermatol. Venerol"},{"issue":"9","key":"95096_CR21","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1001\/jama.2013.1099","volume":"309","author":"KL Winthrop","year":"2013","unstructured":"Winthrop, K. L. et al. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes Zoster. JAMA 309 (9), 887\u2013895. https:\/\/doi.org\/10.1001\/jama.2013.1099 (2013).","journal-title":"JAMA"},{"issue":"7","key":"95096_CR22","first-page":"406","volume":"44","author":"F Maltz","year":"2019","unstructured":"Maltz, F., Fidler, B. & Shingrix A new herpes Zoster vaccine. P T. 44 (7), 406\u2013433 (2019).","journal-title":"P T"},{"issue":"1","key":"95096_CR23","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1136\/annrheumdis-2019-215882","volume":"79","author":"V Furer","year":"2020","unstructured":"Furer, V. et al. 2019 Update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann. Rheum. Dis. 79 (1), 39\u201352. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215882 (2020).","journal-title":"Ann. Rheum. Dis."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95096-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95096-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95096-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T01:02:16Z","timestamp":1759626136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-95096-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,30]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["95096"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-95096-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5340480\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,30]]},"assertion":[{"value":"27 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was approved by institutional review boards at the University of Dicle. All participants provided informed consent by checking a box on a self-administered online informed consent form indicating their agreement to participate in the study. All stages of the research were carried out in accordance with the current guidelines and regulations of ethics in research with human beings.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethics approval and consent to participate"}}],"article-number":"33737"}}